Propolis for Patients With Chronic Kidney Disease.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Kidney Diseases
- Inflammation
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: In this clinical trial, participants with CKD under conservative treatment will be instructed to use 20 drops of standardized green propolis alcohol extract (16% w / v) diluted in 1 glass of water, daily for 2 months before to sleep. The control group will not receive any intervention in those first two months, and then the groups will be crossed and will receive the same amount of propolis as the first group.Masking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Health Services Research
Participation Requirements
- Age
- Between 18 years and 65 years
- Gender
- Both males and females
Description
Chronic kidney disease (CKD) has chronic systemic inflammation as an important component of multifactorial origin, a factor related to both the progression and outcomes of CKD, being involved in all causes of mortality in these patients, such as cardiovascular disease. In this context, some nutritio...
Chronic kidney disease (CKD) has chronic systemic inflammation as an important component of multifactorial origin, a factor related to both the progression and outcomes of CKD, being involved in all causes of mortality in these patients, such as cardiovascular disease. In this context, some nutritional strategies have been proposed as an adjuvant therapeutic alternative to modulate inflammation, starting from the consolidated knowledge of the role of nutrients and bioactive compounds on the expression of genes related to inflammation and oxidative stress, factors that feed on each other. In view of this scenario, propolis, a substance made up of a combination of several chemical components with broad potential biological activity, appears as a promising alternative to modulate inflammation in patients with CKD. However, clinical evidence to assess the effects of propolis in patients with CKD is scarce, and there are no studies that have investigated its effects on gene expression and markers related to inflammation in these patients. Thus, the present project proposes a longitudinal study of the clinical trial type that aims to evaluate the effects of propolis alcoholic extract on transcription factors and inflammatory markers in patients with CKD.
Tracking Information
- NCT #
- NCT04411758
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon